VG-1000™ is a powerful immune system modulator for the biological prevention and treatment of cancer. It is a non-toxic, organic product which acts much like a vaccine to unmask cancerous cells as they mutate into malignancies, and enhances the person’s immune system ability to control or eliminate the cancer.
Case studies using VG-1000™ therapy
Read the transcript of a seminar entitled:
Comprehensive Cancer Care: Integrating Complementary & Alternative Therapies. Trophoblastic Hormones and Cancer: A Breakthrough in Treatment?
Unlike most therapies that are cytotoxic, VG-1000™ therapy is designed to weaken or suppress factors within the tumor that “turn off” the normal immune defenses of the patient, and enable the patient’s immune system to respond against the cancer.
The Russian physician, Dr. Valentin I. Govallo, MD, Ph.D., originally developed this revolutionary immunologic theory through studies of the parallels between the mother-fetus and host-tumor immune interaction systems.
VG-1000 is a vaccine-like biological response modifier acting against cancer; it is based on specific cells extracted from human placenta.
This unique product has a history that starts at the beginning of the last century. In 1901 theScottish embryologist, John Beard, rigorously trained in Germany, became a lecturer in embryology at the University of Edinburgh, one of the world’s great medical schools. He was the first to notice that the cancer cells bear a marked resemblance to the cells that normally surrounds the healthy, developing embryo, called the trophoblast cells.
It is the trophoblast that attach themselves onto and aggressively eat a hole in the uterus.
These cells burrow deeply and implant the embryo beneath the womb’s surface and becomes the chorionic villi as the fetus’ half of the placenta.
The trophoblast’s behavior is anarchistic, aggressive and relentless. It is primitive, corrosive, invasive and “wild”.
What other type of cell is known to behave in such an aggressive, invasive manner despite all the effort at rejection made by the immune system?
The answer is, of course, the CANCER cell.
This astounding concept gives John Beard a brilliant flash of inspiration while literally seated at the microscope. He, familiar with the behavior of the trophoblast in pregnancy studies, observed the behavior of malignant, live cancer cells under microscopic examination. He summed it up in these words: “These ( malignant cells) behave just like trophoblast!”
Beard published his conclusions in “The Lancet” for February 1905, and his treatment of cancers in the same publication in 1906 and 1907, where they can be found to this day.
Cancer, said Beard, is simply trophoblast in the wrong place at the wrong time, triggered into malignant life by what we would call hormones and carcinogens.
Then, in the middle of the Beard furor, World War I broke out, and later the rise of new “magical“ radiation therapy and crude chemotherapy directed medical interest away from
Beard’s thesis and embryonic cell/ placenta therapy for the treatment of cancer. Except in some academic circles, his ideas concerning the origin of cancer have languished in the dusty stack rooms of medical history, spurned by modern oncology in favor of newer theories.
But increasingly it is becoming apparent that long before molecular biology was born, Beard may have hit upon a core truth :
STEM CELLS may ultimately lie at the root of many kinds of cancer!
While Beard himself would not have been aware of the existence of stem cells, his theory concerning the origins of cancer is remarkably compatible with the concept of stem cells as the source of malignancy . Researchers have found that malignant stem cells causes
acute and chronic myelogenous leukemia, and were able to identify cancer stem cells in blood cancers as well as in brain and breast tumors. In certain stomach cancers the cells that initiate the malignancy originate not in the tissue of the stomach itself, but are actually stem cells that have migrated there from the bone marrow .(Sent to the stomach in a response to an infection (Helicobacter pilori) as part of the body’s attempt to heal itself.) From the University of Michigan :
“In contrary to what is generally assumed, not all tumor cells are equally capable of causing metastatic cancer. In fact in experimental breast tumors only a tiny fraction -less than one percent- of tumor cells are actually capable of metastasis. These highly malignant cells are identifiable as stem cells”
A Russian scientist Dr. Valentin I Govallo, disappointed by the failures of his cancer research and treatment, theorized that the immune system itself was hindering the activity of the immune system, emitting certain “blocking factors”. Since some of these blocking factors seem to bear a striking resemblance to those emitted by an embryo during pregnancy, Govallo had the brilliant idea of using placental extracts to immunize the patient against the fetus like behavior of the cancer cells. He found that an extract of human chorionic villi, effectively blocks all reactions of cell immunity, when added to a test tube of white blood cells.
And in cancer patients he found a quantitative reduction of the tumor mass, after immunization with placental extract, and decreased production of blocking factors, just as a decrease in the production of blocking factors reduces tumor mass.
Even if VG-1000 is not literally a vaccine, in such a situation, the injected tissue extract can be viewed as a conditional equivalent of an anti-cancer vaccine.
Govallo said that it is not yet exactly clear how the placental extract effect works, the statistics in his book show a 77.1% 5 year survival rate. He published his results in
The Immunology of Pregnancy and Cancer, Nova Science Publishers, Commack, New York, ISBN 1-56072-096-4.
His first “prototype” placental anticancer extracts were crude, natural compounds which had to be shipped in dry ice.
Dr. Valentin I. Govallo passed away in 2004 and his personal website is banned and don’t exist anymore.
However, if you want to take a look in his questions and answers and case histories, click on the navigate bar on the left side.
Since1999, however, there was a second generation extract, VG-1000, which had all the advantages of a modern product: it was lyophilized . standardized and manufactured under strict quality control rules. Due to its amino acid content, it was accepted in several countries, as a food supplement in a (drink) ampoule. However since 2007 only available as a basic suppositories made on a pilot laboratory scale. . However since 2007 Dr. William van Ewijk using nano technology in cooperation with the research department of pharmacy of a well known Asian University could develop the Vg-1000 extract in a transdermal skin patch.